A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
Abstract
AD: atopic dermatitis AE: adverse events JAK: Janus kinase mTORC1: mammalian target of rapamycin complex 1 RA: rheumatoid arthritis STAT: signal transducer and activator of transcription INTRODUCTION The Janus kinase (JAK) family is a group of tyrosine kinases that is coupled to the cytoplasmic signal transducer of transcription (STAT) factors and mediates cytokine signaling. Four different JAKs, namely JAK1, JAK2, JAK3, and tyrosine kinase, harbor different cytokine receptors relevant to the pathophysiology of many inflammatory skin diseases, including atopic dermatitis (AD), psoriasis, and alopecia areata. Therefore, several JAK inhibitors have reached the market or are still in clinical development as a novel therapeutic option for inflammatory diseases. However, some experts pose concerns about the potential of unexpected adverse effects (AEs) that result from the involvement of unintended pathways along with the target ones. JAK inhibitors have undergone many in-practice studies and clinical trials related to safety concerns. Although the severity, frequencies, and characteristics of AEs are slightly different for each JAK inhibitor, there are common AEs that are frequently observed, like upper respiratory tract infection, headache, herpes simplex infection, and acne. The occurrence of acne has been associated with oral JAK inhibitors, especially in the population with AD, compared with other indications. However, a recent study in Denmark, showed similar 12-month…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 8 participants or records.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.